UI-014 is under clinical development by Korea United Pharm and currently in Phase I for Endocrine Gland Disorders. According to GlobalData, Phase I drugs for Endocrine Gland Disorders have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how UI-014’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
UI-014 overview
UI-014 is under development for the treatment of endocrine, unspecified nutritional, metabolic diseases and hyperlipidaemia. It is administered through oral route. The drug candidate is an incrementally modified drug.
Korea United Pharm overview
Korea United Pharm (KUP) is a pharmaceutical company that produces, markets, sells and distributes pharmaceutical and other healthcare products. It offers incrementally modified drug, anti-cancer, prescription, OTC products, and others. The company provides anti-cancer products such as bleomycin sulfate, carboplatin, cyclophosphamide, dactinomycin and daunorubicin HCl, among others. KUP provides API products such as talniflumate, simvastatin, paroxetine and carvedilol. The company offers prescription products such as iohexol, arginine thiazolidine carboxylate, domperidone maleate, adefovir dipivoxil, entecavir, trimebutine maleate and omeprazole enteric granule, among others. Its products are used in the therapeutic areas of gastrointestinal, cardiovascular, hematopoietic, respiratory, central nervous system, musculoskeletal, endocrine and metabolic and other disorders. The company operates through its branch offices located in the Philippines, Vietnam, Myanmar, China and others. KUP is headquartered in Sejong, South Korea.
For a complete picture of UI-014’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
